Ann Arbor, MI: Women suffering from chronic pelvic pain (CPP) are frequently consuming CBD to mitigate their symptoms, and they are also using it in lieu of other prescription medications, according to data published in the Journal of Minimally Invasive Gynecology.
Researchers affiliated with the University of Michigan, Department of Obstetrics and Gynecology assessed prevalence and patterns of CBD consumption in a cohort of 1,382 women with fibromyalgia and CPP.
Over one-third of respondents identified as current consumers of CBD. Among these consumers, 81 percent said that the use of CBD products “improved their pain.” Seventy-six percent of users reported substituting CBD for other medications, including opioids, NSAIDS, gabapentinoids, and benzodiazepines. Patients also reported perceived benefits in their sleep, anxiety, depression, and in their overall health after initiating the use of CBD products.
The results are consistent with those of prior studies similarly finding that a growing percentage of women are using cannabis and similar products to effectively mitigate chronic pelvic pain and to reduce their reliance on prescription opioids.
Full text of the study, “Cannabidiol use, substitution for medications, and perceptions of effectiveness in women with chronic pelvic pain,” appears in the Journal of Minimally Invasive Gynecology. Additional information on cannabis and chronic pain and cannabis and fibromyalgia is available from NORML. Further information about cannabis substitution effect is available from the NORML fact sheet, “Relationship Between Marijuana and Opioids.”